Kakyung Kim

Archives
Log in
Subscribe
September 25, 2026

๐Ÿ“ˆ econ-radar 2026-09-25 ยท AI ์ž์œจ ๊ณผํ•™ (autonomous AI science)

๐Ÿ“ˆ econ-radar 2026-09-25 ยท AI ์ž์œจ ๊ณผํ•™ (autonomous AI science)

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-09-25

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿ’Š CAR-T ์ž๊ฐ€๋ฉด์—ญ ํ™•์žฅ์˜ ๋‚™๊ด€๋ก ์ด ํ˜„์‹ค์˜ ์žฅ๋ฒฝ์„ ๋งŒ๋‚ฌ๋‹ค. Novartis๊ฐ€ rap-cel ์ž๊ฐ€๋ฉด์—ญ ์ž„์ƒ ์ „์ฒด๋ฅผ ์ค‘๋‹จํ•˜๋ฉฐ 3๋ช…์˜ ์‚ฌ๋ง์„ ๊ณต๊ฐœํ–ˆ๊ณ , BMS๋„ ์—ฐ์ด์–ด ์ž„์ƒ ๋“ฑ๋ก์„ ๋ฉˆ์ท„๋‹ค.

๐Ÿงฌ Anthropic Claude ์—์ด์ „ํŠธ๋“ค์ด 19์–ต ๋‹จ๋ฐฑ์งˆ ํด๋Ÿฌ์Šคํ„ฐ๋ฅผ 21์‹œ๊ฐ„ ์ž์œจ ํƒ์ƒ‰ํ•ด ๋ฏธ๊ธฐ์ˆ  ๋ฐ•ํ…Œ๋ฆฌ์˜คํŒŒ์ง€ ํšจ์†Œ ์‹œ์Šคํ…œ ART๋ฅผ ๋ฐœ๊ฒฌํ–ˆ๋‹ค. AI ์—์ด์ „ํŠธ๊ฐ€ ์Šค์Šค๋กœ ๊ณผํ•™ ๋ฐœ๊ฒฌ์— ๋‚˜์„  ์ฒซ ๊ณต์‹ ๊ธฐ๋ก์ด๋‹ค.

๐Ÿ“ˆ ๋ฏธ 10๋…„๋ฌผ์ด 5.22%๊นŒ์ง€ ์น˜์†Ÿ์•˜๊ณ  Brent๋Š” $105๋ฅผ ๋„˜๊ฒผ๋‹ค. ๋‚ด์ผ(9/26) FOP ์น˜๋ฃŒ์ œ zilurgisertib FDA ๊ฒฐ์ •์ด ๋‚˜์˜ค๋ฉฐ, ์›”๋ง(9/30) BMS Mavacamten ์ฒญ์†Œ๋…„ PDUFA๋„ ๊ธฐ๋‹ค๋ฆฐ๋‹ค.

Today's Top 5

Bio

1. NovartisยทBMS CAR-T ์ž๊ฐ€๋ฉด์—ญ ์ž„์ƒ ์ด์ค‘ ์ค‘๋‹จ โ€” Novartis 3๋ช… ์‚ฌ๋ง, ์ž๊ฐ€๋ฉด์—ญ ํ™•์žฅ ๋…ผ๋ฆฌ ์žฌ๊ฒ€ํ† 

Novartis๊ฐ€ rap-cel(rapcabtagene autoleucel)์˜ ์ž๊ฐ€๋ฉด์—ญ ์ž„์ƒ 8๊ฑด ์ „๋ถ€๋ฅผ ์ผ์‹œ ์ค‘๋‹จํ–ˆ๋‹ค. ์ ์‘์ฆ์€ SLEยท์ „์‹ ๊ฒฝํ™”์ฆ(SSc)ยท๋ฅ˜๋งˆํ‹ฐ์Šค๊ด€์ ˆ์—ผ(RA)ยทANCA ํ˜ˆ๊ด€์—ผยท์ค‘์ฆ๊ทผ๋ฌด๋ ฅ์ฆ(MG)ยท๋‹ค๋ฐœ์„ฑ๊ฒฝํ™”์ฆ(MS) ๋“ฑ์ด๋‹ค. ์ด์œ ๋Š” ์„ธ ํ™˜์ž๊ฐ€ ๋ฉด์—ญํšจ๊ณผ์„ธํฌ ์—ฐ๊ด€ ํ˜ˆ๊ตฌํƒ์‹์ฆํ›„๊ตฐ(IEC-HS, immune effector cellโ€“associated hemophagocytic syndrome)์œผ๋กœ ์‚ฌ๋งํ•œ ๊ฒƒ. ํ˜ˆ์•ก์•” ์ž„์ƒ์€ ๊ณ„์† ์ง„ํ–‰ํ•œ๋‹ค. BMS๋„ zola-cel(zolacabtagene autoleucel)์˜ ์ž๊ฐ€๋ฉด์—ญ ์ž„์ƒ ๋“ฑ๋ก์„ ๋ฉˆ์ท„๋‹ค. BMS ์‚ฌ๋ก€๋Š” ์น˜๋ช…์  ๊ฒฐ๊ณผ ์—†์ด ์—ผ์ฆ ๋ฐ˜์‘์ด ๋ฐœ์ƒํ–ˆ๋‹ค.

โ†— FierceBiotech

Bio

2. [ํ›„์†] Zilurgisertib(FOP) PDUFA D-1 โ€” ๋‚ด์ผ(9/26) FDA ๊ฒฐ์ •, ์„ธ๊ณ„ ์ตœ์ดˆ ๊ฒฝ๊ตฌ FOP ์น˜๋ฃŒ์ œ ํ›„๋ณด

Mirum Pharmaceuticals(MIRM)ยทIncyte(INCY) ๊ณต๋™๊ฐœ๋ฐœ ๊ฒฝ๊ตฌ ALK2 ์–ต์ œ์ œ zilurgisertib์˜ PDUFA๊ฐ€ ๋‚ด์ผ 9์›” 26์ผ์ด๋‹ค. ์ ์‘์ฆ์€ 12์„ธ ์ด์ƒ ์„ฌ์œ ์ดํ˜•์„ฑ์ฆ(Fibrodysplasia Ossificans Progressiva, FOP). PROGRESS Phase 2์—์„œ 48์ฃผ ์‹ ๊ทœ ์ด์†Œ์„ฑ๊ณจํ™”(HO) ๋ณ‘๋ณ€ ํ˜•์„ฑ์„ 99.9% ์–ต์ œํ–ˆ๋‹ค. Priority ReviewยทOrphan Drug ์ง€์ •. MIRMยทINCY ์ฃผ๊ฐ€ ๊ฒฐ์ • ์ „์•ผ ๊ฐ•์„ธ.

โ†— Incyte IR

AIBio

3. Anthropic Claude, ๋ฐ•ํ…Œ๋ฆฌ์˜คํŒŒ์ง€ ๋ฏธ๊ธฐ์ˆ  ํšจ์†Œ 'ART' ์ž์œจ ๋ฐœ๊ฒฌ โ€” AI ์ž์œจ ๊ณผํ•™ ๋ฐœ๊ฒฌ ์ฒซ ๊ณต์‹ ๊ธฐ๋ก

Anthropic์˜ ์ƒ๋ช…๊ณผํ•™ ์—ฐ๊ตฌ๊ทธ๋ฃน(2026๋…„ ๋ด„ ์„ค๋ฆฝ)์ด ์ฒซ preprint๋ฅผ ๋ฐœํ‘œํ–ˆ๋‹ค. Claude ์—์ด์ „ํŠธ ์•ฝ 950๊ฐœ๊ฐ€ 21์‹œ๊ฐ„ ๋™์•ˆ 2์–ต1์ฒœ๋งŒ ํ† ํฐ์„ ์‚ฌ์šฉํ•ด 19์–ต ๊ฐœ ๋‹จ๋ฐฑ์งˆ ํด๋Ÿฌ์Šคํ„ฐ ๋ฐ์ดํ„ฐ๋ฒ ์ด์Šค๋ฅผ ์ž์œจ ํƒ์ƒ‰ํ–ˆ๋‹ค. ๋ฐœ๊ฒฌ๋œ ART(array-associated reverse transcriptases)๋Š” ์—ญ์ „์‚ฌํšจ์†ŒยทํŒŒํŠธ๋„ˆ ์œ ์ „์žยท๊ทœ์น™์  ๊ฐ„๊ฒฉ์˜ DNA ๋ฐ˜๋ณต ๋ฐฐ์—ด ์„ธ ์š”์†Œ๋กœ ๊ตฌ์„ฑ๋œ๋‹ค. ๋ฐ˜๋ณต ๋ฐฐ์—ด ๊ตฌ์กฐ๊ฐ€ CRISPR ๋ฐฐ์—ด๊ณผ ์œ ์‚ฌํ•ด ํ–ฅํ›„ ์œ ์ „์žํŽธ์ง‘ ๋„๊ตฌ๋กœ ์ด์–ด์งˆ ๊ฐ€๋Šฅ์„ฑ์ด ์žˆ๋‹ค. ์•„์ง ๋™๋ฃŒ์‹ฌ์‚ฌ ์ „ preprint๋‹ค.

โ†— Anthropic

Market

4. ๋ฏธ 10๋…„๋ฌผ 5.22%ยทBrent $105+ ๋™์‹œ ๊ณ ๊ณต โ€” ์ฝ”์Šคํ”ผ ์ถ”์„ ํ›„ 9/28 ์žฌ๊ฐœ ์ฒซ ๊ด€๋ฌธ

๋ฏธ 10๋…„๋ฌผ ๊ตญ์ฑ„ ์ˆ˜์ต๋ฅ ์ด 9์›” 24์ผ 5.22%๊นŒ์ง€ ๊ธ‰๋“ฑํ–ˆ๋‹ค. ์ „์ผ(5.13%) ๋Œ€๋น„ 9bp ์ƒ์Šน์œผ๋กœ ์ดํ‹€ ์—ฐ์† ์‹ ๊ณ ๊ฐ€ ํ–‰์ง„์ด๋‹ค. 30๋…„๋ฌผ๋„ 5.50%๋กœ 2004๋…„ ์ดํ›„ ์ตœ๊ณ ์น˜๋‹ค. ์‹œ์žฅ์€ 10์›” FOMC 25bp ์ถ”๊ฐ€ ์ธ์ƒ ํ™•๋ฅ ์„ 70%๋กœ ๋ฐ˜์˜ํ–ˆ๋‹ค. ๋™์‹œ์— Brent ์›์œ ๋Š” $105๋ฅผ ๋„˜๊ฒผ๋‹ค. UNGA ๋ฏธยท์ด๋ž€ ํšŒ๋‹ด์—์„œ ๋ณ„๋‹ค๋ฅธ ๋ŒํŒŒ๊ตฌ๊ฐ€ ์—†์ž ํ˜ธ๋ฅด๋ฌด์ฆˆ ์œ„ํ—˜ ํ”„๋ฆฌ๋ฏธ์—„์ด ์œ ์ง€๋๋‹ค.

โ†— CNBC

AI

5. GoogleยทOpenAIยทAnthropic, 'Frontier AI Standards Agency' ์„ค๋ฆฝ ์ตœ์ข… ํ˜‘์˜ โ€” ์ž์œจ ๊ทœ์ œ์˜ ์ƒˆ ๊ธฐ์ค€์„ 

์„ธ ํ”„๋ก ํ‹ฐ์–ด AI ๊ธฐ์—…์ด 'Standards Authority for Frontier AI(FASF)' ์„ค๋ฆฝ ์ตœ์ข… ๋‹จ๊ณ„์— ์žˆ๋‹ค. 2026๋…„ ๋ง~2027๋…„ ์ดˆ ์ถœ๋ฒ” ๋ชฉํ‘œ๋กœ ์ •๋ถ€ ๊ฐ๋… ์—†๋Š” ์ž์œจ ๊ทœ์ œ ๊ตฌ์กฐ๋‹ค. ๊ธฐ๋Šฅ์€ โ‘  ๋ฐฐํฌ ์ „ ์ œ3์ž ๋ชจ๋ธ ํ…Œ์ŠคํŠธ ์ง€์›, โ‘ก AI ์‚ฌ๊ณ ยท๋ณด์•ˆ ์ธ์‹œ๋˜ํŠธ ๋ณด๊ณ  ๊ธฐ์ค€, โ‘ข ๊ธฐ์—… ์ž๋ฐœ์  ์•ˆ์ „ ์„œ์•ฝ, โ‘ฃ ๊ฐ์‚ฌ ๊ธฐ๊ด€ ์ž๊ฒฉ ๊ธฐ์ค€์ด๋‹ค. ๋ฏธ ์ƒ์› AI ๋ฒ•์•ˆ(Cruz-Klobuchar) ๋งˆํฌ์—…์ด ๊ต์ฐฉ ์ƒํƒœ์ธ ์ƒํ™ฉ์—์„œ ์—…๊ณ„๊ฐ€ ๋จผ์ € ๊ทœ์ œ ์„ค๊ณ„ ๊ถŒํ•œ์„ ์„ ์ ํ•˜๋Š” ์ „๋žต์ด๋‹ค.

โ†— BankInfoSecurity

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

AI๊ฐ€ ์Šค์Šค๋กœ '๋ฐœ๊ฒฌ'์˜ ์ฃผ์ฒด๋กœ ๋‚˜์„œ๊ธฐ ์‹œ์ž‘ํ–ˆ๋‹ค. ๊ฒ€์ฆ์ด ๊ด€๊ฑด์ด๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-09-25

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-09-26 ยท Section 232 ์˜์•ฝํ’ˆ ๊ด€์„ธ: ๋น…ํŒŒ๋งˆ์˜ ๊ณต๊ธ‰๋ง ๊ฐˆ๋ฆผ๊ธธ Older โ†’ ๐Ÿ“ˆ econ-radar 2026-09-24 ยท ํฌํ† ๋ฅ˜ ๊ณต๊ธ‰๋ง (rare earth supply chain)
Powered by Buttondown, the easiest way to start and grow your newsletter.